Table 1Acute coronary syndrome: Clopidogrel/aspirin compared with placebo/aspirin (CURE – 12 months)

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of studies; number of subjectsRisk of bias (design/quality)ConsistencyDirectnessPrecisionRR (95% confidence interval)High, moderate, low, insufficient
All-cause mortality
1/N= 12562Low (RCT/Good)ConsistentIndirectPrecise0.93 (0.81 to 1.07)aModerate
Cardiovascular mortality
1/N= 12562Low (RCT/Good)ConsistentIndirectPrecise0.93 (0.80 to 1.10)Moderate
1/N= 12562Low (RCT/Good)ConsistentIndirectPrecise0.78 (0.68 to 0.90)Moderate
Major bleeding
1/N= 12562Low (RCT/Good)ConsistentIndirectImprecise1.37 (1.13 to 1.67)aModerate
Withdrawal due to adverse events
1/N= 12562NRInsufficient

Calculated by OR EPC using StatsDirect.

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Newer Antiplatelet Agents
Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report [Internet].
Ketchum K, Peterson K, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2011 Jun.
Copyright © 2011 by Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.